Inpatient primary prophylaxis of cancer-associated thromboembolism (CAT).
Anticoagulation
Hospitalized thrombosis
Oncology
Prophylaxis
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
01
02
2022
accepted:
09
05
2022
pubmed:
3
6
2022
medline:
28
9
2022
entrez:
2
6
2022
Statut:
ppublish
Résumé
Cancer-associated thrombosis (CAT) increases morbidity and mortality in oncology patients. The risk of CAT is increased with hospitalization for acute medical illness. The goal of this review will be to examine the available evidence for (1) risk assessment and (2) primary thromboprophylaxis, (3) international published guideline recommendations, and (4) future directions to manage oncology patients admitted for an acute medical illness. A review was performed for each subject to gather information on the available evidence and recommendations available for oncology patients hospitalized for an acute medical illness. Risk assessments for thrombosis are primarily developed and validated in the general population. There is not a risk assessment that has specifically been developed and validated in oncology patients hospitalized for an acute medical illness. Most evidence for thromboprophylaxis of oncology patients is from sub-group analysis of larger randomized-controlled trials in the general population. Evidence is conflicting and suggests an individualized approach evaluating the risk-benefit of thromboprophylaxis. The strength of recommendations of international guidelines is limited because of the available evidence. Guidelines usually recommend utilizing and/or offering thromboprophylaxis to oncology patients hospitalized for an acute medical illness barring contraindications. Future evidence needs to improve risk assessments and knowledge of the appropriate agent, dose, and duration of thromboprophylaxis if indicated. Evidence for risk assessments and primary prophylaxis for oncology patients hospitalized for acute medical illness appears limited, with many research opportunities available to improve understanding on management of this patient population.
Identifiants
pubmed: 35655046
doi: 10.1007/s00520-022-07137-9
pii: 10.1007/s00520-022-07137-9
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
8501-8509Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P (2018) Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 10(10)
Patell R, Zwicker JI (2020) Inpatient prophylaxis in cancer patients: where is the evidence? Thromb Res. 191(Suppl 1):S85–s90
doi: 10.1016/S0049-3848(20)30403-5
Sharma BK, Flick MJ, Palumbo JS (2019) Cancer-associated thrombosis: a two-way street. Semin Thromb Hemost. 45(6):559–568
doi: 10.1055/s-0039-1693472
Donnellan E, Khorana AA (2017) Cancer and venous thromboembolic disease: a review. Oncologist. 22(2):199–207
doi: 10.1634/theoncologist.2016-0214
Rodrigues CAFR, Kalil Filho R, Novis YA, Hoff PM (2010) Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis. 30(1):67–78
doi: 10.1007/s11239-010-0441-0
Khorana AA, Carrier M, Garcia DA, Lee AY (2016) Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 41(1):81–91
doi: 10.1007/s11239-015-1313-4
Fernandes CJ, Morinaga LTK, Alves JLJ et al (2019) Cancer-associated thrombosis: the when, how and why. Eur Respir Rev 28(151)
Fuentes HE, Tafur AJ, Caprini JA (2016) Cancer-associated thrombosis. Dis Mon. 62(5):121–158
doi: 10.1016/j.disamonth.2016.03.003
Scotté F, Leroy P, Chastenet M, Aumont L, Benatar V, Elalamy I (2019) Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. Cancers (Basel) 11(1)
Cohen AT, Tapson VF, Bergmann J-F et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 371(9610):387–394
doi: 10.1016/S0140-6736(08)60202-0
Kahn SR, Lim W, Dunn AS et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141(2 Suppl):e195S–e226S
doi: 10.1378/chest.11-2296
Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI (2014) Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 127(1):82–86.e81
doi: 10.1016/j.amjmed.2013.09.015
Parker A, Peterson E, Lee AYY et al (2018) Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer. J Thromb Haemost. 16(7):1321–1326
doi: 10.1111/jth.14139
Patell R, Rybicki L, McCrae KR, Khorana AA (2017) Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool. Am J Hematol. 92(6):501–507
doi: 10.1002/ajh.24700
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 111(10):4902–4907
doi: 10.1182/blood-2007-10-116327
Bosch FTM, Mulder FI, Kamphuisen PW et al (2020) Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Adv. 4(20):5215–5225
doi: 10.1182/bloodadvances.2020003115
Mandalà M, Falanga A, Piccioli A et al (2006) Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 59(3):194–204
Mario Mandala MCP, Anna Falanga et al (2019) Guidelines on venous thromboembolism in patients with solid tumors. Ital Assoc Med Oncol
Mandalà M, Falanga A, Roila F (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 22:vi85–vi92
Bang SM, Jang MJ, Kim KH et al (2014) Prevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice Guidelines. J Korean Med Sci 29(2):164–171
Muñoz Martín AJ, Gallardo Díaz E, García Escobar I et al (2020) SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol 22(2):171–186
Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M (2014) Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol 16(12):1079–1090
Easaw JC, Shea-Budgell MA, Wu CM et al (2015) Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol 22(2):133–143
Watson HG, Keeling DM, Laffan M, Tait RC, Makris M (2015) Guideline on aspects of cancer-related venous thrombosis. Br J Haematol 170(5):640–648
Wojtukiewicz MZ SE, Tomkowski W et al (2016) Guidelines for the prevention and treatment of venous thromboembolism in patients with cancers treated conservatively. Oncol Clin Pract 12:67–91
Pachón V, Trujillo-Santos J, Domènech P et al (2018) Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus. TH Open 2(4):e373–e386
Key NS, Khorana AA, Kuderer NM et al (2020) Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 38(5):496–520
Farge D, Frere C, Connors JM et al (2019) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566–e581
Lyman GH, Carrier M, Ay C et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927–974
National Comprehensive Cancer Network (2022) Cancer-Associated Venous Thromboembolic Disease (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf . Accessed 1 June 2022
Cohen A, Davidson B, Gallus A (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 332:325–329
doi: 10.1136/bmj.38733.466748.7C
Leizorovicz A, Cohen A, Turpie A (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 110:874–879
doi: 10.1161/01.CIR.0000138928.83266.24
Samama M, Cohen A, Darmon J (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 341:793–800
doi: 10.1056/NEJM199909093411103
Budd AC, Rhodes M, Forster AJ, Noghani P, Carrier M, Wells PS (2021) Prescribing patterns and outcomes of venous thromboembolism prophylaxis in hospitalized medical and cancer patients: Observations from the Ottawa Hospital. Thromb Res. 197:144–152
doi: 10.1016/j.thromres.2020.11.013
Zwicker JI, Roopkumar J, Puligandla M et al (2020) Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Adv. 4(10):2254–2260
doi: 10.1182/bloodadvances.2020001804
Osataphan S, Patell R, Chiasakul T, Khorana AA, Zwicker JI (2021) Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Adv. 5(8):2055–2062
doi: 10.1182/bloodadvances.2020004118
Cohen AT, Spiro TE, Büller HR et al (2013) Rivaroxaban for Thromboprophylaxis in acutely ill medical patients. N Engl J Med. 368(6):513–523
doi: 10.1056/NEJMoa1111096
Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for Thromboprophylaxis in medically ill patients. N Engl J Med 365(23):2167–2177
doi: 10.1056/NEJMoa1110899
Cohen AT, Harrington RA, Goldhaber SZ et al (2016) Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 375(6):534–544
doi: 10.1056/NEJMoa1601747
Ageno W, Lopes RD, Yee MK et al (2020) Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. J Thromb Thrombolysis. 49(2):214–219
doi: 10.1007/s11239-019-01943-5
Li A, Carlson JJ, Kuderer NM et al (2020) Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer. 126(8):1736–1748
doi: 10.1002/cncr.32724
Gómez-Outes A, Avendaño-Solá C, Terleira-Fernández AI, Vargas-Castrillón E (2014) Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. Pharmacoeconomics. 32(9):919–936
doi: 10.1007/s40273-014-0175-5
Figueroa R, Alfonso A, López-Picazo J et al (2019) Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience. Clin Transl Oncol. 21(6):805–809
doi: 10.1007/s12094-018-1986-1
Piazza G, Nguyen TN, Morrison R et al (2012) Patient education program for venous thromboembolism prevention in hospitalized patients. Am J Med. 125(3):258–264
doi: 10.1016/j.amjmed.2011.09.012
Nicholson M, Chan N, Bhagirath V, Ginsberg J (2020) Prevention of venous thromboembolism in 2020 and beyond. J Clin Med 9(8)
Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ (2007) Venous thromboembolism in the outpatient setting. Arch Intern Med. 167(14):1471–1475
doi: 10.1001/archinte.167.14.1471